Figure 1.

Risk of CTRCD According to Pon and Aryl Activity Ratios at Doxorubicin Completion

CTRCD-free survival curves comparing highest versus lowest tertiles of Pon and Aryl ratios at 2 months relative to baseline; models adjusted for baseline LVEF, cancer therapy regimen, age, race, hypertension, smoking, BMI, disease stage, diabetes, and statin use at baseline. Aryl = arylesterase; BMI = body mass index; CTRCD = cancer therapy–related cardiac dysfunction; LVEF = left ventricular ejection fraction; Pon = paraoxonase.